<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228266</url>
  </required_header>
  <id_info>
    <org_study_id>CMM-EM</org_study_id>
    <nct_id>NCT01228266</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Transplantation in MS</brief_title>
  <acronym>CMM-EM</acronym>
  <official_title>Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Saiz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized Phase II study, masked and crossed-over with placebo to evaluate&#xD;
      the safety and tolerability of autologous mesenchymal stem cell transplantation in patients&#xD;
      with active multiple sclerosis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Ended the recruitment in June 2012 for low enrollement accrual&#xD;
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety as number of severe events along 1 year, and efficacy in terms of cumulative number of gadolinium-enhancing lesions in MRI at 6 months and at the end of the study</measure>
    <time_frame>12 months</time_frame>
    <description>The coprimary endpoints were safety and efficacy in terms of cumulative number of gadolinium-enhancing lesions in MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate effects on MS disease activity measured by: clinical variables, MRI, OCT, immunological analysis and quality of life scales</measure>
    <time_frame>12 months</time_frame>
    <description>clinical outcomes (number of relapses and change in the EDSS); MRI-based measures and OCT. Immunological evaluation as exploratory analysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>autologous mesenchymal stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs suspension media. The treatment will be reversed at 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous mesenchymal stem cells</intervention_name>
    <description>A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS</description>
    <arm_group_label>autologous mesenchymal stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Inflammatory forms of MS&#xD;
&#xD;
               1. Relapsing-remitting MS (RRMS) patients&#xD;
&#xD;
               2. Secondary progressive MS (SPMS) patients with continued relapses&#xD;
&#xD;
               3. Primary progressive MS (PPMS) patients with enhancing MRI lesions and positive&#xD;
                  CSF (oligoclonal banding)&#xD;
&#xD;
          2. Age 18-50 years&#xD;
&#xD;
          3. Disease duration &gt;= 2 and &gt;= 10 years&#xD;
&#xD;
          4. EDSS 3.0 - 6.5&#xD;
&#xD;
          5. Progression, continued relapses or worsening MRI after at least a year of attempted&#xD;
             therapy evidenced by:&#xD;
&#xD;
               1. Increase of &gt;= 1 EDSS point (if baseline EDSS &lt;= 5.0) or 0.5 EDSS points (if&#xD;
                  baseline EDSS &gt;= 5.5), or quantifiable, objective evidence of equivalent&#xD;
                  progression&#xD;
&#xD;
               2. &gt;= 1 moderate-severe relapses in past 18 months&#xD;
&#xD;
               3. &gt;= 1 Gadolinium enhancing lesions (double or triple dose Gadolinium)&#xD;
&#xD;
               4. &gt;= 1 new T2 lesion&#xD;
&#xD;
               5. For PPMS only, &gt;= 1 Gadolinium enhancing lesions&#xD;
&#xD;
          6. Has given informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. SPMS without ongoing relapses&#xD;
&#xD;
          2. PPMS without positive CSF or Gadolinium enhancing lesions&#xD;
&#xD;
          3. &lt;= 3 months since treatment with any immunosuppressive therapy&#xD;
&#xD;
          4. &lt;=1 month since last treatment with interferon-B or glatiramer acetate&#xD;
&#xD;
          5. Corticosteroid treatment &lt;= 30 days&#xD;
&#xD;
          6. Relapse &lt;= 60 days&#xD;
&#xD;
          7. History of cancer or clinical or laboratory results indicative of severe systemic&#xD;
             diseases, including infection for HIV, Hepatitis B or C&#xD;
&#xD;
          8. Any metallic or electronic device that precludes from undergoing MRI&#xD;
&#xD;
          9. Pregnancy or lactation&#xD;
&#xD;
         10. Current treatment with an investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Saiz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurology Service, Hospital Clinic de barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>October 25, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2010</study_first_posted>
  <last_update_submitted>February 12, 2014</last_update_submitted>
  <last_update_submitted_qc>February 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Albert Saiz</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

